Openbookopenbook
Equity
The Cooper Companies, Inc(COO)
USD --+0.00%
Reward48Moderate
Risk40Moderate
📊75%Data
COO
+0.0 · +0.00%
USD · NASDAQ
The Cooper Companies, Inc | Healthcare
Balanced
Market Cap:16.49Bn
ℹ️
Reward Rating
48
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
40
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on COO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $91.00.

What is The Cooper Companies, Inc?

, together with its subsidiaries, develops, manufactures, and markets contact lens wearers.

COO · Verdict

Moderate reward · moderate risk

COO's standout is cash flow, while growth remains the main concern.

Based on 88% data coverage

COO · Verdict

What’s working & what to watch

Strengths 1

  • Cash flow70/100

    11% free-cash-flow margin

Watchouts 1

  • Growth39/100

    Rev +7.3% CAGR · earnings -1.0%

Model-based scoring. For information only — not financial advice.

What is The Cooper Companies, Inc?

, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 16.49B, and a P/E ratio of 44.4x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (48)

The scoring profile indicates limited reward potential at this time, with profitability and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap16.49B
P/E Ratio44.3529
Dividend YieldN/A
52 Week High92.84
52 Week Low61.78
Last AnnualOctober
IPO Date12/30/1983
IncorporatedUSA
Shares Outstanding196M
No. of Employees15,000
IndustryMedical Instruments & Supplies
ExchangeNASDAQ
Beta1.027
CurrencyUSD
Websitewww.coopercos.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.